This week, we have a conversation with the founder, director and chief scientific advisor of Alessa Therapeutics, Pamela Munster.
Alessa Therapeutics
Alessa Therapeutics recently announced positive preliminary phase 1 safety and efficacy data for its prostate cancer treatment Enolen.
This was the first study to demonstrate that the FDA-approved prostate cancer compound enzalutamide can be safely and locally administered to the prostate via sustained drug eluting implants.
Recent key data presented by researchers at the NCI at the European Association of Urology Congress in London included:
All 20 patients enrolled in the initial cohort were successfully implanted. These implantations achieved very high intraprostatic enzalutamide levels with minimal systemic drug exposure and resulted in no delay to surgery.
Pre-radical prostatectomy MRI’s conducted for 18/20 patients (2 pending) showed a reduction in tumour volume in 84% of the lesions over an average duration of 35 days.
There were no reported effects on testosterone levels or negative effects on sexual function.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
